Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implant

Bioventus’ protracted buyout bid ultimately fell apart and opened the door to Smith & Nephew.

After losing 1.8% in the past year, Smith & Nephew plc (LON:SN.) institutional owners must be relieved by the recent gain

Key Insights Significantly high institutional ownership implies Smith & Nephew's stock price is sensitive to their...

Smith & Nephew plc 2023 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Smith & Nephew plc in conjunction with their 2023 Q3 earnings call.

Smith & Nephew plc (SNN) Q3 2023 Earnings Call Transcript

Smith & Nephew plc (NYSE:NYSE:SNN) Q3 2023 Earnings Conference Call November 2, 2023 4:30 AM ETCompany ParticipantsDeepak Nath - Chief Executive...

Shareholders in Smith & Nephew (LON:SN.) are in the red if they invested three years ago

As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...

Smith & Nephew Getting More Interesting As A Contrarian Idea

Smith & Nephew shares look increasingly attractive as a contrarian call. Read more to see a detailed analysis on SNN stock.

Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of Munich

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company specialising in orthopaedics, advanced wound management and sports medicine, is pleased to announce the opening of the purpose-built Smith+Nephew Academy Munich, a new centre for surgical innovation and training.

Smith & Nephew PLC: An In-depth Analysis of its Dividend Performance

Smith & Nephew PLC(NYSE:SNN) recently announced a dividend of $0.29 per share, payable on 2023-11-01, with the ex-dividend date set for 2023-10-05. Using the data from GuruFocus, let's deep dive into Smith & Nephew PLCs dividend performance and assess its sustainability. Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions.

The Zacks Analyst Blog Highlights Abbott Laboratories, Koninklijke Philips and Smith & Nephew

Abbott Laboratories, Koninklijke Philips and Smith & Nephew are included in this Analyst Blog.

Smith & Nephew's (LON:SN.) Returns On Capital Not Reflecting Well On The Business

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...